RCT | Discontinuing RAS inhibitors in patients with advanced CKD did not result in a slower decline in eGFR.

Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

In this randomized trial, the discontinuation of renin–angiotensin system inhibitors in patients with advanced chronic kidney disease did not lead to a significant between-group difference in the long-term rate of decline in the eGFR. #KidneyWk https://t.co/81EIwG5FQ0 pic.twitter.com/nHNmzlPbHV

— NEJM (@NEJM) November 3, 2022